Background: The recent discovery of a monoclonal antibody specific for TCR-Cb-1 (encoded by TCRCB1) heralded a new method for ab-T-cell clonality assessment by flow cytometry. Each ab-T-cell contains a b-chain constant region encoded by either TCRCB1 or TCRCB2. 1 Methods: Since 25 March 2021, following non-Hodgkin lymphoma immunophenotyping, selected specimens were further analysed with custom 5-colour panel tube(s) containing mouse monoclonal anti-TCR-Cb-1 (clone JOVI-1) conjugated to fluorescein isothiocyanate, anti-CD45 and additional antibodies to allow gating of T-cell populations of interest, using a stain-lysewash method. TCR-Cb-1 expression of <15% or >85% is considered clonal. Results: 24 clonality assessments were performed to date. Indications include aberrant T-cell immunophenotype (n=10), marked abnormal CD4:CD8 skewing (n=6), monitoring of established abnormal T-cell clones (n=4), mycosis fungoides staging (n=3) and T-cell lymphocytosis (n=1). In cases with negative-clonality (n=13), median TCR-Cb-1positivity was 40% (interquartile range 34-47%). Excluding lost to follow-up (n=1), clinicopathological correlation was established in 21/23 cases. Lack of correlation was secondary to clonality of uncertain significance (n=1) and sampling (n=1, aberrant immunophenotype detected only by immunohistochemistry, T-cells identified by flow cytometry lacked aberrant immunophenotype and were nonclonal). Conclusion: Concordant with published data, 1,2 our experience supports the utility of this method for establishing ab-T-cell clonality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.